Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016

BACKGROUND: Only 5-fluorouracil (5-FU), cisplatin, and gemcitabine have been reimbursed for metastatic pancreatic cancer (mPC) treatment in Taiwan since 2003. It is uncertain whether the reimbursement of S-1 in June 2014 might change the treatment pattern and improve the survival of mPC patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Wen-Chi, Chen, Yen-Yang, Hung, Chia-Yen, Chen, Jen-Shi, Lu, Chang-Hsien, Chang, Pei-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421872/
https://www.ncbi.nlm.nih.gov/pubmed/30936744
http://dx.doi.org/10.2147/CMAR.S196300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421872/
https://www.ncbi.nlm.nih.gov/pubmed/30936744
http://dx.doi.org/10.2147/CMAR.S196300

Ejemplares similares